present government cannot be surprised at the lack of public confidence in its health policies. Regardless of repeated assertions to the contrary, so called reforms will inevitably be taken as the prelude to wholesale retreat from the spirit of Beveridge. Perhaps, if the present administration wants to distance itself from the more strident forms of Thatcherism and convince the public of its genuine support for the NHS as it was originally conceived, no better opportunity could be provided than the anniversary of the Beveridge report. Otherwise, the public and those working in the NHS will continue to fear that preparations are being made to turn back the clock to the prewar system so effectively discredited by the Medical Planning Council in 1942. CHARLES Insurers, however, have also sought to identify applicants who are at higher than average risk of becoming HIV seropositive in the future. Following guidelines from the Association of British Insurers in 1987, virtually all British life insurers now ask applicants on their proposal form whether they have had an HIV antibody test and whether they have had any advice or counselling about AIDS. Depending on their age and sex, and the level of cover sought, applicants are sent a supplementary questionnaire asking them whether they belong to a so called 'high risk' group. Companies may also request a personal medical attendance report from the applicant's general practitioner.
Requiring applicants to disclose whether they have previously been tested for HIV -even when the result was negative-has caused the greatest concern. The House of Commons social services committee condemned this form of question in 1989, a view supported by the BMA.34 Furthermore, many health professionals who counsel patients believe that companies may withhold life insurance or impose higher premiums on people who take the test.5 A Department of Health survey concluded that the number of people likely to be deterred from being tested for HIV by questions on insurance forms was "certainly in the thousands, possibly in the tens of thousands."6 The Association of British Insurers nevertheless rejected a proposal from the Terrence Higgins Trust that insurers should change their question to: "Have you tested positive on an HIV antibody test?" North American guidelines on underwriting, accepted voluntarily by the life insurance industries contrast substantially with British practice.78 The Canadian guidelines state unequivocally that "no adverse underwriting decision" should be based on a previous consultation or testing for HIV exposure with a negative or unknown result. The American guidelines give as alternative recommendations that insurers may ask only about a prior positive antibody test or that they may not ask about prior tests at all, and these have been enacted into the law in several states. Both the Canadian and American guidelines preclude questions directed at the applicant's sexual orientation.
A recent initiative by health advisers and doctors in Riverside Health Authority sought to clarify this issue for their patients.9 After consultation, the Association of British Insurers produced a leaflet for patients who were considering being tested for HIV. This stated that "people should be reassured that if they have an HIV antibody test they will face no difficulty in obtaining future life insurance because of having a test. Existing life insurance policy will not be affected whatever the result." A survey found that 37% of men and 46% of women stated that reading this leaflet had increased their likelihood of being tested for HIV whereas only 7% of men and no women were discouraged from having a test by this information. Despite this apparent move by the Association of British Insurers to remove this barrier several related issues remain unresolved.
Firstly, the association has not changed its statement of practice, which says that "having had a negative HIV test will not of itself prevent someone from attaining life insurance or even affect the cost, providing there are no adverse risk factors present."'°That proviso is a significant qualification, and the statement goes on to draw a distinction between having tests for "routine" and "non-routine purposes." This ignores the fact that any negative test would be accompanied by counselling that forms part of the educational process in encouraging safer sexual and other behaviour thereafter.
Secondly, the leaflet which was provided for the Riverside survey stated that people who test negative for HIV will face no difficulties in obtaining future life insurance because of having the test, and the chairman of the association's medical committee has made a similar statement." If that is so then continuing to ask for this information has no justification. But if, as suggested in a later passage in the leaflet and the different wording of a recent association leaflet issued to general practitioners, the very fact of having had a test will trigger the despatch of a supplementary questionnaire and may also lead to a request for a medical report or further test-when these steps would otherwise not have been taken-the applicant is being treated less favourably than if he or she had never had a test. Thus the statement as it stands is misleading. 2 Moreover, even if insurers consider that knowing that an applicant previously tested negative for HIV is useful in life underwriting, any supposed benefit from asking this question is severely limited by the lack of truthful answers. In the Riverside study 28% of patients said that they would not divulge the result of their HIV test to any insurance company. 9 The best efforts of the Department of Health, the Terrence Higgins Trust, and health professionals who counsel patients about HIV tests have therefore left the practices of British insurers unchanged and the concerns raised by the Department of Health unanswered. 1992;304: 1692.
Skin lightening creams containing hydroquinone
The case for a temporary ban Over the counter products containing hydroquinone, the active ingredient of skin lightening creams, are frequently inadequately labelled and often exceed the limit of 2% on the hydroquinone concentration.'2 Although trading standards departments are right to draw attention to such problems, this can obscure a more crucial issue: are creams containing hydroquinone safe in any concentration?
Hardwick and colleagues established a causal link between hydroquinone and exogenous ochronosis, the permanent sooty black, coarse pigmentation seen in black women on areas of the skin exposed to the sun.3 It seems unlikely that breakdown products of hydroquinone or contaminants' are to blame as identical effects have been described after the use of at least 30 different formulations.3 The early descriptions of exogenous ochronosis in black South African women referred to advanced cases5; some women had used creams containing up to 6% of hydroquinone.6 After prolonged medical pressure the South African government agreed in 1980 to set a 2% upper limit on hydroquinone for cosmetic use,7 and Britain,8 the United States,9 and Nigeria followed suit. The reason for choosing the 2% maximum is obscure, for it was based not on any logical toxicological limit but on tests of cutaneous irritancy"' and contact dermatitis." It probably seemed a "sensible" figure at the time'2 given the earlier reports of ochronosis, which had emphasised the use of stronger concentrations of hydroquinone.
Hardwick and colleagues argued that the high prevalence of ochronotic changes in those using hydroquinone skin lighteners (69%) is far more compatible with a toxic side effect from a drug with a low therapeutic index than with an idiosyncratic reaction.' As Schulz and Sher pointed out, the amount of hydroquinone absorbed into the skin depends on the frequency and duration of application,'3 which are beyond the control of the chemist. This is why dermatologists have always regarded the safety of even the lowest concentrations of hydroquinone as doubtful.
The results of several studies support their misgivings. In a study of women attending a South African gynaecology clinic Weiss found evidence of ochronosis in nearly one third, half of whom had used creams only since 1983 (three years after the banning of creams stronger than 2%). " Many reports from Europe and the United States document unequivocal changes of ochronosis in people who have used creams containing 2%'5'9 and even 1% hydroquinone.20 In response, one manufacturer has pointed out that the concentrations of hydroquinone in these creams has not been determined and is likely to be much stronger than 2%.2' This hardly seems a plausible explanation for all reported cases, especially given the many cases that continue to be seen in South Africa, where a 2% limit has been in operation for 12 years (R Weiss, personal communication). Nevertheless, it seems prudent for local trading standards offices to test creams claiming to contain 2% hydroquinone in future cases of suspected ochronosis.
Without population based surveys, extrapolating from isolated hospital based reports probably grossly underesti-
